| |
Join Us
 Interested in a job at Signum? Visit our job postings section for a listing of our open positions. |
|
|
|
About Signum » Board of Directors
Jeffry Stock, PhD
Chairman
Directs our scientific effort. A tenured full professor in the departments of Molecular Biology and Chemistry at Princeton University and a co-founder of Cadus Pharmaceuticals (KDUS), he is one of the world’s leading experts in signal transduction and global cellular regulation with over 150 original scientific articles in the area. He is an elected fellow of the American Society of Microbiology and a winner of the Humbolt Prize. He is on the editorial boards of the Journal of Biochemistry and BMC Microbiology, and he serves on the Centers Review Committee for the National Institute of Drug Abuse. Professor Stock is best known for his seminal work on the biochemistry of signal transduction in micro-organisms. He discovered both the system that regulates PP2A to control the cellular phosphoregulatory networks in higher organisms and the CAAX-tail modification system that globally regulates Ras and other G-Proteins involved in signal transduction. He is the force behind our science, which is why our laboratory is located near his Princeton research laboratory.
Back to top
Gregory Stock, PhD
CEO
Has led previous entrepreneurial efforts and is the architect of Signum’s business strategy. Prior to Signum, Dr. Stock directed the Program on Medicine, Technology and Society at UCLA’s School of Medicine. He has broad scientific, media and business experience, holds an MBA from Harvard Business School, where he was a Baker Scholar and won the Freund-Porter Entrepreneurship award, and he has a PhD in biophysics from Johns Hopkins. He has made more than 1000 radio and television appearances, including Talk of the Nation, Charlie Rose, Oprah Winfrey and Larry King, given more than 100 invited lectures to organizations including Johnson & Johnson, GlaxoSmithKline, Microsoft, Nissan, Ernst & Young, Lloyds and the EPA, published 60 articles and written 8 books, including Redesigning Humans, which won the Kistler Prize for science, and The Book of Questions, which sold 2.5 million copies and was translated into 17 languages. A leading authority on the broad impacts of advanced technologies in the life sciences, he was invited to submit an advisory memo to President Clinton, has debated science policy with Jeremy Rifkin, Francis Fukuyama, Leon Kass and others, and has been profiled by the Wall Street Journal, New York Times, Lancet and MIT Tech Review.
Back to top
Stephen Modzelewski
Has been active in the field of finance since 1982, when he joined Salomon Brothers, which is now a part of Citicorp. In his 5 year tenure there, he created various mathematical models for valuing fixed income securities, developed the conceptual framework for "option adjusted spread," which has become a standard analytical metric for complex fixed income securities, and codified the rules for "Liar's Poker." In 1988, he and a colleague left Salomon and established the hedge fund Parsec Trading Corp., which has been a successful fixed income arbitrage fund for over 13 years. Their keen interest in incentive structures led to Parsec being the only major hedge fund where the managers receive a share of both profits and losses. At the end of 2002, Modzelewski established his own trading and investment firm, Maple Engine L.L.C., a private multi-strategy investment and trading fund focusing on speculative trading and venture investment. He serves on the Boards of the Reason Foundation and the Institute for Justice.
Back to top
Kunio Yamada
We are fortunate to have this visionary leader as a member of our board. Kunio, Rohto’s President and CEO is the fourth generation of company leadership. He is a graduate of Japan’s prestigious Tokyo University and has done post graduate work overseas. He is a young, energetic and dynamic leader with a progressive global vision for the growth and development of Rohto’s shareholder value. He has led Rohto’s visionary long term investments in R&D and has directed the continuous and dramatic growth of sales in recent years in spite of a weak economy in Japan. In the short term he has focused all activities on the goals of achieving further growth in Rohto’s operations and improving earnings by introducing value-added products and using the overseas network to expand operations. Strategically Rohto will continue to concentrate on sales of beauty care products and reinforce R&D capabilities, primarily at Rohto Research Village Kyoto, in order to develop and launch new products globally. Our mutual research collaboration will contribute to Rohto’s strategic goals, while enhancing the commercial, business development and market focus of Signum’s research priorities. We look forward to a productive and long term relationship.
Back to top |
|
